Commitments and Contingencies - Additional Information (Details) - USD ($) |
3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2023 |
Jun. 30, 2022 |
Jun. 30, 2023 |
Jun. 30, 2022 |
|
| Commitments and Contingencies [Line Items] | ||||
| Monthly fee included in minimum lease payment | $ 578,000 | |||
| Research and development expense | $ 11,797,000 | $ 9,514,000 | 24,232,000 | $ 18,684,000 |
| Wuxi Agreement | WuXi Advanced Therapies | ||||
| Commitments and Contingencies [Line Items] | ||||
| Early termination fee | 1,500,000 | $ 1,500,000 | ||
| Lease expiration month | 18 months | |||
| Research Service Agreement | Children's Hospital of Philadelphia | ||||
| Commitments and Contingencies [Line Items] | ||||
| Research and development expense | 0 | $ 0 | $ 0 | $ 166,000 |
| Liability related to agreement | $ 480,000 | $ 480,000 | ||
| X | ||||||||||
- Definition Commitments and contingencies disclosure. No definition available.
|
| X | ||||||||||
- Definition Lease Expiration Month No definition available.
|
| X | ||||||||||
- Definition Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The amount of early contract termination fees included in liabilities subject to compromise. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of operating lease expense. Excludes sublease income. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|